News

Low-cost generic drug programs have large gaps in coverage for core evidence-based CVD medications: Study

Low-cost generic drug programs have large gaps in coverage for core evidence-based CVD medications: Study

Credit: CC0 Public Domain A cross-sectional study of 19 low-cost generic programs (LCGPs) found that their medication coverage for six cardiovascular diseases (CVD) varied significantly between programs. Of all analyzed programs, Mark Cuban Cost Plus Drug Company demonstrated the most comprehensive coverage for all diseases included in the study. The findings are published in Annals

Significant progress in cell separation technology

Significant progress in cell separation technology

Early detection allows for timely intervention in many diseases before they progress to a severe stage, often at a lower treatment cost. This is particularly crucial in the case of cancer, as the stage of cancer development at the time of initial diagnosis significantly influences the patient’s prognosis and survival rate…

A framework of biomarkers for brain aging

A framework of biomarkers for brain aging

China and the world are facing severe population aging and an increasing burden of age-related diseases. Aging of the brain causes major age-related brain diseases, such as neurodegenerative diseases and stroke. Identifying biomarkers for the effective assessment of brain aging and establishing a brain aging assessment system could facilitate the development of brain aging intervention